3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
3
Waldenstrom Macroglobulinemia
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, B-Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
10
ofatumumab
8
fludarabine
6
Rituximab
5
fludarabine phosphate
4
Bendamustine Hydrochloride
4
venetoclax
3
obinutuzumab
3
ibrutinib
3
acalabrutinib
3
Melphalan
3
pirtobrutinib
2
Whole-Body Irradiation
2
Vincristine
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Lenalidomide
2
Immunotherapy, Adoptive
2
Busulfan
2
Bortezomib
2
Alemtuzumab
2
zanubrutinib
1
thymoglobulin
1
tenofovir alafenamide
1
pomalidomide
1
pivalyloxymethyl butyrate
1
pegaspargase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia, B-Cell
×
ARQ531
×
Clear all
NCT04728893
2026-05-26
MK-1026-003
Merck Sharp & Dohme LLC
Phase 2
Recruiting
490 enrolled